SCHEMBL22022904

SCHEMBL22022904

CCCCc1ccc(-c2cccc(CCC(=O)Nc3cc(Cl)ccc3C(=O)O)c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 12/20 0.65
▸ KDM4E B2RXH2 2/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ KCNK2 O95069 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ ALOX15 P16050 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ACLY P53396 1/20 0.50
▸ GRIK1 P39086 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22022910 0.93 KDM4E (0.72) HCAR2KDM4EALDH1A1KCNK2SMN1; SMN2
SCHEMBL22022913 0.91 ACLY (0.59) HCAR2KDM4EALDH1A1KCNK2SMN1; SMN2
SCHEMBL22022880 0.91 HCAR2 (0.66) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL22022898 0.89 HCAR2 (0.70) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL22022923 0.88 HCAR2 (0.67) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL22022926 0.87 HCAR2 (0.68) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL22071191 0.86 HCAR2 (0.77) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL22022863 0.85 HCAR2 (0.60) HCAR2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL19511947 0.85 HCAR2 (0.56) HCAR2KDM4EALDH1A1KCNK2ACLY
SCHEMBL22022893 0.84 MEN1 (0.65) HCAR2KDM4EALDH1A1KCNK2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US claimed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP claimed
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES KCNK2, KCNT2, KCNT1 HCAR2 165/4885KDM4E 967/4885ALDH1A1 3537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback